9407 - 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

May 24, 2012

Via SEDAR

Alberta Securities Commission
4th Floor, 300 – 5th Avenue S.W.
Calgary, AB T2P 3C4

Re: Quest PharmaTech Inc. ("Quest") – SEDAR Filing of Material Contracts

Enclosed are copies of Quest's material contracts entered into during the period February 1, 2011 to January 31, 2012. This SEDAR filing is pursuant to the requirements of National Instrument 51-102.

Sincerely,

Pierre Vermette
CFO
Quest PharmaTech Inc.
Direct Line: (780) 448-1400, ext. 217
Email: pierre@questpharmatech.com

AMENDMENT TO CONVERTIBLE DEBENTURE AGREEMENTS

THIS AGREEMENT made as of the 1st day of March, 2011

BETWEEN:

QUEST PHARMATECH INC.
("Quest")

and

(lender name information redacted)
(the "Lenders")

WHEREAS Quest and the Lenders entered into an agreement dated March 22, 2010 entitled "Amendment to Convertible Debenture Agreements";

AND WHEREAS Quest and the Lenders wish to amend one provision under the March 22, 2010 agreement.

NOW THEREFORE the parties agree as follows:

1. The maturity date under the March 22, 2010 agreement is hereby amended to September 22, 2011.

2. The terms and conditions of this agreement are valid until September 22, 2011. The parties may renew this agreement with new terms and conditions after September 22, 2011, if such terms and conditions are acceptable to both parties.

3. All of the other terms and conditions under the March 22, 2010 agreement are valid.

This Agreement shall be binding upon and for the benefit of the successors and assigns of both parties.

IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.

QUEST PHARMATECH INC.

Per: ______________________

Per: ______________________

(lender name information redacted)

____

____

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Demand Loan Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: Thomas Woo Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
March 25, 2011	Demand Loan - Cash Contribution Received	$20,000
	Subtotal	$20,000
	Tax	N/A
Total		$20,000

This demand loan carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated March 25, 2011

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

DEMAND PROMISSORY NOTE

AMOUNT:

DUE: Thirty days after demand

FOR VALUE RECEIVED, QUEST PHARMATECH INC. of 9407 – 20 Avenue, Edmonton, Alberta, Canada, T6N 1E5 promises to pay to the order of **(IAN McCONNAN)** of (address information redacted), on demand, the sum of fifty thousand dollars ($50,000.00) with interest at eight percent (8%) per annum. Interest shall be payable monthly on the last day of the month until the demand promissory note is paid in full.

IN THE EVENT OF DEFAULT, interest shall be payable at the rate of eighteen percent (18%) per annum calculated from the date of default.

MADE as of the 30th day of March, 2011.

ON BEHALF OF QUEST PHARMATECH INC

____

Dr. Ragupathy ("Madi") Madiyalakan
Chief Executive Officer
Quest PharmaTech Inc.

____

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

DEMAND PROMISSORY NOTE

AMOUNT: $50,000.00 **DUE:** Thirty days after demand

FOR VALUE RECEIVED, QUEST PHARMATECH INC. of 9407 – 20 Avenue, Edmonton, Alberta, Canada, T6N 1E5 promises to pay to the order of **IAN McCONNAN** of (address information redacted), on demand, the sum of fifty thousand dollars ($50,000.00) with interest at eight percent (8%) per annum. Interest shall be payable monthly on the last day of the month until the demand promissory note is paid in full.

IN THE EVENT OF DEFAULT, interest shall be payable at the rate of eighteen percent (18%) per annum calculated from the date of default.

MADE as of the 2nd day of May, 2011.

ON BEHALF OF QUEST PHARMATECH INC

____
Dr. Ragupathy ("Madi") Madiyalakan
Chief Executive Officer
Quest PharmaTech Inc.

____
Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Demand Loan Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (Lender name redacted) Address: (address information redacted)

Effective Date of Demand Loan	**Description**	**Amount**
June 21, 2011	Demand Loan - Cash Contribution Received	$50,000
	Subtotal	$50,000
	Tax	N/A
Total		$50,000

This demand loan carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated June 21, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Demand Loan Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (Lender name redacted) Address: (address information redacted)

Effective Date of Demand Loan	**Description**	**Amount**
Aug 04, 2011	Demand Loan - Cash Contribution Received	$20,000
	Subtotal	$20,000
	Tax	N/A
Total		$20,000

This demand loan carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated August 04, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Bridge Financing Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (lender name redacted) Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
Aug 04, 2011	Bridge Financing - Cash Contribution Received	$10,000
	Subtotal	$10,000
	Tax	N/A
Total		$10,000

This bridge financing carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated August 04, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST PHARMATECH INC.

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

August 16, 2011

VIA Fax (+82-31-420-4733) and Courier

KMH Co., Ltd.
#405, Megavalley 799
Gwanyang-Dong
Dongan-Gu
Anyang-city
South Korea, 431-767

Re: Quest PharmaTech Inc. ("Quest") – Distribution Rights Agreement dated October 15, 2006, as amended May 8, 2007 – Notice of Termination

Dear Sir / Madam,

Pursuant to Part 8.0 of the October 15, 2006 Distribution Rights Agreement, as amended May 8, 2007 (the "Agreement") between Quest and KMH Co., Ltd. ("KMH"), this letter represents Quest's notice of termination of the Agreement in connection with KMH's breach/default under the Agreement as follows:

> Subsequent to the completion of the clinical trials in September, 2010, Quest requested a marketing strategy plan pursuant to Part 7.0 of the May 8, 2007 amendment.

Since we have not received this marketing strategy report to date, we are providing notice of termination of the Agreement under Part 8.0 thereof.

KMH has 15 days following receipt of this notice to remedy such breach/default. Please provide your response notice accordingly.

Sincerely,

Pierre Vermette

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.
Ph # 448-1400, ext 217
Email: pierre@questpharmatech.com

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Bridge Financing Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (lender name redacted) Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
Aug 19, 2011	Bridge Financing - Cash Contribution Received	$20,000
	Subtotal	$20,000
	Tax	N/A
Total		$20,000

This bridge financing carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated August 19, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Bridge Financing Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (lender name redacted) Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
Sept 13, 2011	Bridge Financing - Cash Contribution Received	$15,000
	Subtotal	$15,000
	Tax	N/A
Total		$15,000

This bridge financing carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated September 13, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

AMENDMENT TO CONVERTIBLE DEBENTURE AGREEMENTS

THIS AGREEMENT made as of the 11th day of October, 2011

BETWEEN:

QUEST PHARMATECH INC.
("Quest")

and

(lender name information redacted)
(the "Lenders")

WHEREAS Quest and the Lenders entered into an agreement dated March 1, 2011 entitled "Amendment to Convertible Debenture Agreements";

AND WHEREAS Quest and the Lenders wish to amend one provision under the March 1, 2011 agreement.

NOW THEREFORE the parties agree as follows:

1. The maturity date under the March 1, 2011 agreement is hereby amended to March 22, 2012.

2. The terms and conditions of this agreement are valid until March 22, 2012. The parties may renew this agreement with new terms and conditions after March 22, 2012, if such terms and conditions are acceptable to both parties.

3. All of the other terms and conditions under the March 1, 2011 agreement are valid.

4. Pursuant to the March 31, 2011 agreement dealing with collateral modification, the Collateral for the Convertible Debenture includes dermatology and oncology applications of the SonoLight Technology.

This Agreement shall be binding upon and for the benefit of the successors and assigns of both parties.

IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.

QUEST PHARMATECH INC.

Per: ______________________

Per: ______________________

(lender name information redacted)

____

____

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Demand Loan Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (Lender name redacted) Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
Dec 06, 2011	Demand Loan - Cash Contribution Received	$100,000
	Subtotal	$100,000
	Tax	N/A
Total		$100,000

This demand loan carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated December 06, 2011

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.

QUEST

9407 – 20 Avenue.
Edmonton, Alberta
Canada T6N 1E5

Phone: (780) 448-1400
Fax: (780) 416-0324
info@questpharmatech.com

Demand Loan Receipt

Payee Name: Quest PharmaTech Inc. Address: 9407 20 Avenue Edmonton, Alberta T6N 1E5	Payer Name: (Lender name redacted) Address: (address information redacted)	
Effective Date of Demand Loan	**Description**	**Amount**
Jan 24, 2012	Demand Loan - Cash Contribution Received	$50,000
	Subtotal	$50,000
	Tax	N/A
Total		$50,000

This demand loan carries an annual interest rate of 8.0 %, interest payable monthly, is unsecured and has no fixed terms of repayment.

Dated January 24, 2012

Thomas Woo
VP Product Development
Quest PharmaTech Inc.

Pierre Vermette
Chief Financial Officer
Quest PharmaTech Inc.